Multiple sclerosis: Diagnosis, disease-modifying therapy and prognosis
- PMID: 35362004
- DOI: 10.31128/AJGP-07-21-6103
Multiple sclerosis: Diagnosis, disease-modifying therapy and prognosis
Abstract
Background: Multiple sclerosis (MS) is a multifocal inflammatory central nervous system disorder. There are now many highly effective disease-modifying therapies (DMTs) available as treatment options, which have a significant impact on disease activity and long-term disability.
Objective: The aim of this article is to provide a concise overview of the diagnosis, DMTs and prognosis of MS.
Discussion: The diagnosis of MS is made on clinicoradiological grounds to prove dissemination of disease in both time and space in the nervous system. While the expanding options of DMTs have had a significant impact on disability, they make medication selection for individual patients more complicated. Patients with MS often have a model of care shared between the neurologist and the general practitioner. This review article summarises the key aspects of the diagnosis, DMTs and prognosis of MS relevant to the general practitioner.
Similar articles
-
Multiple sclerosis: current and emerging disease-modifying therapies and treatment strategies.Mayo Clin Proc. 2014 Feb;89(2):225-40. doi: 10.1016/j.mayocp.2013.11.002. Mayo Clin Proc. 2014. PMID: 24485135 Review.
-
Multiple Sclerosis in Children: Differential Diagnosis, Prognosis, and Disease-Modifying Treatment.CNS Drugs. 2022 Jan;36(1):45-59. doi: 10.1007/s40263-021-00887-w. Epub 2021 Dec 23. CNS Drugs. 2022. PMID: 34940954 Free PMC article. Review.
-
Disease-modifying therapy usage in patients with multiple sclerosis in France: A 6-year population-based study.Rev Neurol (Paris). 2021 Dec;177(10):1250-1261. doi: 10.1016/j.neurol.2021.04.006. Epub 2021 Jul 10. Rev Neurol (Paris). 2021. PMID: 34253346
-
Understanding Multiple Sclerosis Pathophysiology and Current Disease-Modifying Therapies: A Review of Unaddressed Aspects.Front Biosci (Landmark Ed). 2024 Nov 19;29(11):386. doi: 10.31083/j.fbl2911386. Front Biosci (Landmark Ed). 2024. PMID: 39614433 Review.
-
Diagnosis and Treatment of Multiple Sclerosis: A Review.JAMA. 2021 Feb 23;325(8):765-779. doi: 10.1001/jama.2020.26858. JAMA. 2021. PMID: 33620411 Review.
Cited by
-
Personality traits in patients with multiple sclerosis: their association with nicotine dependence and polypharmacy.Ther Adv Neurol Disord. 2024 Oct 14;17:17562864241279118. doi: 10.1177/17562864241279118. eCollection 2024. Ther Adv Neurol Disord. 2024. PMID: 39411724 Free PMC article.
-
Depression and Anxiety in Association with Polypharmacy in Patients with Multiple Sclerosis.J Clin Med. 2023 Aug 18;12(16):5379. doi: 10.3390/jcm12165379. J Clin Med. 2023. PMID: 37629420 Free PMC article.
-
Effects of Physical Exercise on Neurofilament Light Chain and Glial Fibrillary Acidic Protein Level in Patients with Multiple Sclerosis: A Systematic Review and Bayesian Network Meta-Analysis.J Clin Med. 2025 Jan 27;14(3):839. doi: 10.3390/jcm14030839. J Clin Med. 2025. PMID: 39941510 Free PMC article. Review.
-
The role of microglia in multiple sclerosis: implications for treatment with Bruton's tyrosine kinase inhibitors.Front Immunol. 2025 May 15;16:1495529. doi: 10.3389/fimmu.2025.1495529. eCollection 2025. Front Immunol. 2025. PMID: 40443664 Free PMC article. Review.
-
Knowledge mapping of disease-modifying therapy (DMT) in multiple sclerosis (MS): A bibliometrics analysis.Heliyon. 2024 May 31;10(11):e31744. doi: 10.1016/j.heliyon.2024.e31744. eCollection 2024 Jun 15. Heliyon. 2024. PMID: 38868066 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical